0.00Open3.03Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover2945.11%IV42.88%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry3.03Time Value100Contract SizeAmericanOptions Type0.6354Delta0.2012Gamma2.43Leverage Ratio-15.3550Theta0.0000Rho1.55Eff Leverage0.0002Vega
Shattuck Labs Stock Discussion
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
No comment yet